<bill session="113" type="h" number="1958" updated="2013-11-02T06:35:31-04:00">
  <state datetime="2013-05-14">REFERRED</state>
  <status>
    <introduced datetime="2013-05-14"/>
  </status>
  <introduced datetime="2013-05-14"/>
  <titles>
    <title type="short" as="introduced">Gray Market Drug Reform and Transparency Act of 2013</title>
    <title type="official" as="introduced">To prohibit wholesalers from purchasing prescription drugs from pharmacies, and to enhance information and transparency regarding drug wholesalers engaged in interstate commerce.</title>
  </titles>
  <sponsor id="400090"/>
  <cosponsors/>
  <actions>
    <action datetime="2013-05-14" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2013-05-17">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Business records"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government information and archives"/>
    <term name="Prescription drugs"/>
    <term name="Retail and wholesale trades"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <summary>5/14/2013--Introduced.
Gray Market Drug Reform and Transparency Act of 2013 - Amends the Federal Food, Drug, and Cosmetic Act to: (1) make it a prohibited act and a misbranding for a wholesale distributor of prescription drugs to purchase or receive a prescription drug from a pharmacy or a pharmacist, (2) require annual reporting by wholesale distributors of prescription drugs, (3) require the Secretary of Health and Human Services (HHS) to establish and maintain a national database of information reported by wholesale distributors of prescription drugs and to require such database to include information on actions taken by states against wholesale distributors (e.g., disciplinary actions and license revocations), (4) require the Secretary to assess and collect fees from wholesale distributors of prescription drugs, and (5) require wholesale distributors of prescription drugs to provide to recipients of a prescription drug in shortage the sales price for such drug at the time of its sale and at the time of any prior sale of such drug when it was in shortage.</summary>
</bill>
